Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis
Identifieur interne : 001548 ( Istex/Corpus ); précédent : 001547; suivant : 001549Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis
Auteurs : P. H. Hofschneider ; U. Winter ; E. M. Lemmel ; B. Brölz ; W. Gaus ; S. Schmid ; H. J. Obert ; C. Stetter ; I. O. Auer ; C. Papst ; W. H. Boesken ; H. E. Stierle Ii ; U. Botzenhardt ; W. Reemtsen ; D. Brackertz ; D. Richter ; V. Diehl ; A. K. Von Kalle ; C. G Rtner ; S. Herzig ; J. Goronzy ; C. Weyand ; J. R. Kalden ; F. Strobel ; K. Machalke ; H. H. Peter ; S. Meske ; M. Schattenkirchner ; K. Krüger ; R. Sprekeler ; H. D. Waller ; J. G. Saal ; H. Warnatz ; G. Lemm ; K. Wilms ; T. StolzenburgSource :
- Rheumatology International [ 0172-8172 ] ; 1992-11-01.
Abstract
Summary: The controlled clinical trial reported here is part of a multicenter clinical and basic research project, sponsored by the German Federal Minister of Science and Technology, directed by a standing commission of the president of the Max-Planck-Gesellschaft, and coordinated by the Max-Planck-Institut für Biochemie, München. Overall, 249 patients with rheumatoid arthritis (RA) were enrolled by 16 participating hospitals. In addition to NSAID treatment, patients were randomly given either interferon gamma (IFN-γ) or placebo. In the IFN-γ group, 107 patients were evaluated and in the control group, 116 patients were evaluated. The response rate after 3 months of treatment, according to joint pain indexes, was significantly higher in the IFN-γ group with an error probability of 1%. IFN-γ was able to reduce the quantity of corticosteroids administered. Compared with the control group, the IFN-γ group benefited considering all parameters measured. Most important side effects were transient fever and transient influenza-like symptoms; all other adverse events were comparable in both groups.
Url:
DOI: 10.1007/BF00302149
Links to Exploration step
ISTEX:9D6BE8ED959279DE45398098C485ED3D9FAE729CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis</title><author><name sortKey="Hofschneider, P H" sort="Hofschneider, P H" uniqKey="Hofschneider P" first="P. H." last="Hofschneider">P. H. Hofschneider</name><affiliation><mods:affiliation>Max-Planck-Institut für Biochemie, Martinsried</mods:affiliation></affiliation></author><author><name sortKey="Winter, U" sort="Winter, U" uniqKey="Winter U" first="U." last="Winter">U. Winter</name><affiliation><mods:affiliation>Max-Planck-Institut für Biochemie, Martinsried</mods:affiliation></affiliation></author><author><name sortKey="Lemmel, E M" sort="Lemmel, E M" uniqKey="Lemmel E" first="E. M." last="Lemmel">E. M. Lemmel</name><affiliation><mods:affiliation>Staatliches Rheumakrankenhaus Baden-Baden, Baden Baden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Brolz, B" sort="Brolz, B" uniqKey="Brolz B" first="B." last="Brölz">B. Brölz</name><affiliation><mods:affiliation>Staatliches Rheumakrankenhaus Baden-Baden, Baden Baden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Gaus, W" sort="Gaus, W" uniqKey="Gaus W" first="W." last="Gaus">W. Gaus</name><affiliation><mods:affiliation>Universität Ulm, Ulm, Germany</mods:affiliation></affiliation></author><author><name sortKey="Schmid, S" sort="Schmid, S" uniqKey="Schmid S" first="S." last="Schmid">S. Schmid</name><affiliation><mods:affiliation>Universität Ulm, Ulm, Germany</mods:affiliation></affiliation></author><author><name sortKey="Obert, H J" sort="Obert, H J" uniqKey="Obert H" first="H. J." last="Obert">H. J. Obert</name><affiliation><mods:affiliation>Bioferon biochemische Substanzen GmbH & Co., Laupheim</mods:affiliation></affiliation></author><author><name sortKey="Stetter, C" sort="Stetter, C" uniqKey="Stetter C" first="C." last="Stetter">C. Stetter</name><affiliation><mods:affiliation>Bioferon biochemische Substanzen GmbH & Co., Laupheim</mods:affiliation></affiliation></author><author><name sortKey="Auer, I O" sort="Auer, I O" uniqKey="Auer I" first="I. O." last="Auer">I. O. Auer</name><affiliation><mods:affiliation>Medizinische Universitätsklinik, Luitpoldkrankenhaus, Würzburg</mods:affiliation></affiliation></author><author><name sortKey="Papst, C" sort="Papst, C" uniqKey="Papst C" first="C." last="Papst">C. Papst</name><affiliation><mods:affiliation>Medizinische Universitätsklinik, Luitpoldkrankenhaus, Würzburg</mods:affiliation></affiliation></author><author><name sortKey="Boesken, W H" sort="Boesken, W H" uniqKey="Boesken W" first="W. H." last="Boesken">W. H. Boesken</name><affiliation><mods:affiliation>Medizinische Abteilung, Krankenhaus der Barmherzigen Brüder Trier, Trier, Germany</mods:affiliation></affiliation></author><author><name sortKey="Stierle Ii, H E" sort="Stierle Ii, H E" uniqKey="Stierle Ii H" first="H. E." last="Stierle Ii">H. E. Stierle Ii</name><affiliation><mods:affiliation>Medizinische Abteilung, Krankenhaus der Barmherzigen Brüder Trier, Trier, Germany</mods:affiliation></affiliation></author><author><name sortKey="Botzenhardt, U" sort="Botzenhardt, U" uniqKey="Botzenhardt U" first="U." last="Botzenhardt">U. Botzenhardt</name><affiliation><mods:affiliation>Rheumatologische Abteilung, Rotes Kreuz-Krankenhaus Bremen, Bremen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Reemtsen, W" sort="Reemtsen, W" uniqKey="Reemtsen W" first="W." last="Reemtsen">W. Reemtsen</name><affiliation><mods:affiliation>Rheumatologische Abteilung, Rotes Kreuz-Krankenhaus Bremen, Bremen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Brackertz, D" sort="Brackertz, D" uniqKey="Brackertz D" first="D." last="Brackertz">D. Brackertz</name><affiliation><mods:affiliation>St. Vincenz- und Elisabeth-Hospital Mainz, Mainz, Germany</mods:affiliation></affiliation></author><author><name sortKey="Richter, D" sort="Richter, D" uniqKey="Richter D" first="D." last="Richter">D. Richter</name><affiliation><mods:affiliation>St. Vincenz- und Elisabeth-Hospital Mainz, Mainz, Germany</mods:affiliation></affiliation></author><author><name sortKey="Diehl, V" sort="Diehl, V" uniqKey="Diehl V" first="V." last="Diehl">V. Diehl</name><affiliation><mods:affiliation>Medizinische Universitätsklinik Köln, Koln, Germany</mods:affiliation></affiliation></author><author><name sortKey="Von Kalle, A K" sort="Von Kalle, A K" uniqKey="Von Kalle A" first="A. K." last="Von Kalle">A. K. Von Kalle</name><affiliation><mods:affiliation>Medizinische Universitätsklinik Köln, Koln, Germany</mods:affiliation></affiliation></author><author><name sortKey="G Rtner, C" sort="G Rtner, C" uniqKey="G Rtner C" first="C." last="G Rtner">C. G Rtner</name><affiliation><mods:affiliation>Krankenhaus Porz/Rhein, Abteilung Rheumatologie, Köln</mods:affiliation></affiliation></author><author><name sortKey="Herzig, S" sort="Herzig, S" uniqKey="Herzig S" first="S." last="Herzig">S. Herzig</name><affiliation><mods:affiliation>Krankenhaus Porz/Rhein, Abteilung Rheumatologie, Köln</mods:affiliation></affiliation></author><author><name sortKey="Goronzy, J" sort="Goronzy, J" uniqKey="Goronzy J" first="J." last="Goronzy">J. Goronzy</name><affiliation><mods:affiliation>Medizinische Poliklinik V Heidelberg, Heidelberg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Weyand, C" sort="Weyand, C" uniqKey="Weyand C" first="C." last="Weyand">C. Weyand</name><affiliation><mods:affiliation>Medizinische Poliklinik V Heidelberg, Heidelberg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Kalden, J R" sort="Kalden, J R" uniqKey="Kalden J" first="J. R." last="Kalden">J. R. Kalden</name><affiliation><mods:affiliation>Medizinische Klinik III und Institut für klinische Immunologie und Rheumatologie Erlangen, Erlangen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Strobel, F" sort="Strobel, F" uniqKey="Strobel F" first="F." last="Strobel">F. Strobel</name><affiliation><mods:affiliation>Medizinische Klinik III und Institut für klinische Immunologie und Rheumatologie Erlangen, Erlangen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Machalke, K" sort="Machalke, K" uniqKey="Machalke K" first="K." last="Machalke">K. Machalke</name><affiliation><mods:affiliation>Klinik Lippe, Horn-Bad Meinberg</mods:affiliation></affiliation></author><author><name sortKey="Peter, H H" sort="Peter, H H" uniqKey="Peter H" first="H. H." last="Peter">H. H. Peter</name><affiliation><mods:affiliation>Abteilung Rheumatologie und klinische Immunologie, Medizinische Universitätsklinik Freiburg, Freiburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Meske, S" sort="Meske, S" uniqKey="Meske S" first="S." last="Meske">S. Meske</name><affiliation><mods:affiliation>Abteilung Rheumatologie und klinische Immunologie, Medizinische Universitätsklinik Freiburg, Freiburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Schattenkirchner, M" sort="Schattenkirchner, M" uniqKey="Schattenkirchner M" first="M." last="Schattenkirchner">M. Schattenkirchner</name><affiliation><mods:affiliation>Rheumaeinheit, Medizinische Poliklinik der Universität München, Munchen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Kruger, K" sort="Kruger, K" uniqKey="Kruger K" first="K." last="Krüger">K. Krüger</name><affiliation><mods:affiliation>Rheumaeinheit, Medizinische Poliklinik der Universität München, Munchen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Sprekeler, R" sort="Sprekeler, R" uniqKey="Sprekeler R" first="R." last="Sprekeler">R. Sprekeler</name><affiliation><mods:affiliation>Diakoniekrankenhaus Rotenburg/Wümme, Rotenburg/Wümme, Germany</mods:affiliation></affiliation></author><author><name sortKey="Waller, H D" sort="Waller, H D" uniqKey="Waller H" first="H. D." last="Waller">H. D. Waller</name><affiliation><mods:affiliation>Abteilung Innere Medizin II, Medizinische Klinik Tübingen, Tubingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Saal, J G" sort="Saal, J G" uniqKey="Saal J" first="J. G." last="Saal">J. G. Saal</name><affiliation><mods:affiliation>Abteilung Innere Medizin II, Medizinische Klinik Tübingen, Tubingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Warnatz, H" sort="Warnatz, H" uniqKey="Warnatz H" first="H." last="Warnatz">H. Warnatz</name><affiliation><mods:affiliation>Katholisches Krankenhaus Essen-Werden, Essen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Lemm, G" sort="Lemm, G" uniqKey="Lemm G" first="G." last="Lemm">G. Lemm</name><affiliation><mods:affiliation>Katholisches Krankenhaus Essen-Werden, Essen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Wilms, K" sort="Wilms, K" uniqKey="Wilms K" first="K." last="Wilms">K. Wilms</name><affiliation><mods:affiliation>Medizinische Poliklinik der Universität Würzburg, Wurzburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Stolzenburg, T" sort="Stolzenburg, T" uniqKey="Stolzenburg T" first="T." last="Stolzenburg">T. Stolzenburg</name><affiliation><mods:affiliation>Medizinische Poliklinik der Universität Würzburg, Wurzburg, Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9D6BE8ED959279DE45398098C485ED3D9FAE729C</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1007/BF00302149</idno><idno type="url">https://api.istex.fr/document/9D6BE8ED959279DE45398098C485ED3D9FAE729C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001548</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001548</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis</title><author><name sortKey="Hofschneider, P H" sort="Hofschneider, P H" uniqKey="Hofschneider P" first="P. H." last="Hofschneider">P. H. Hofschneider</name><affiliation><mods:affiliation>Max-Planck-Institut für Biochemie, Martinsried</mods:affiliation></affiliation></author><author><name sortKey="Winter, U" sort="Winter, U" uniqKey="Winter U" first="U." last="Winter">U. Winter</name><affiliation><mods:affiliation>Max-Planck-Institut für Biochemie, Martinsried</mods:affiliation></affiliation></author><author><name sortKey="Lemmel, E M" sort="Lemmel, E M" uniqKey="Lemmel E" first="E. M." last="Lemmel">E. M. Lemmel</name><affiliation><mods:affiliation>Staatliches Rheumakrankenhaus Baden-Baden, Baden Baden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Brolz, B" sort="Brolz, B" uniqKey="Brolz B" first="B." last="Brölz">B. Brölz</name><affiliation><mods:affiliation>Staatliches Rheumakrankenhaus Baden-Baden, Baden Baden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Gaus, W" sort="Gaus, W" uniqKey="Gaus W" first="W." last="Gaus">W. Gaus</name><affiliation><mods:affiliation>Universität Ulm, Ulm, Germany</mods:affiliation></affiliation></author><author><name sortKey="Schmid, S" sort="Schmid, S" uniqKey="Schmid S" first="S." last="Schmid">S. Schmid</name><affiliation><mods:affiliation>Universität Ulm, Ulm, Germany</mods:affiliation></affiliation></author><author><name sortKey="Obert, H J" sort="Obert, H J" uniqKey="Obert H" first="H. J." last="Obert">H. J. Obert</name><affiliation><mods:affiliation>Bioferon biochemische Substanzen GmbH & Co., Laupheim</mods:affiliation></affiliation></author><author><name sortKey="Stetter, C" sort="Stetter, C" uniqKey="Stetter C" first="C." last="Stetter">C. Stetter</name><affiliation><mods:affiliation>Bioferon biochemische Substanzen GmbH & Co., Laupheim</mods:affiliation></affiliation></author><author><name sortKey="Auer, I O" sort="Auer, I O" uniqKey="Auer I" first="I. O." last="Auer">I. O. Auer</name><affiliation><mods:affiliation>Medizinische Universitätsklinik, Luitpoldkrankenhaus, Würzburg</mods:affiliation></affiliation></author><author><name sortKey="Papst, C" sort="Papst, C" uniqKey="Papst C" first="C." last="Papst">C. Papst</name><affiliation><mods:affiliation>Medizinische Universitätsklinik, Luitpoldkrankenhaus, Würzburg</mods:affiliation></affiliation></author><author><name sortKey="Boesken, W H" sort="Boesken, W H" uniqKey="Boesken W" first="W. H." last="Boesken">W. H. Boesken</name><affiliation><mods:affiliation>Medizinische Abteilung, Krankenhaus der Barmherzigen Brüder Trier, Trier, Germany</mods:affiliation></affiliation></author><author><name sortKey="Stierle Ii, H E" sort="Stierle Ii, H E" uniqKey="Stierle Ii H" first="H. E." last="Stierle Ii">H. E. Stierle Ii</name><affiliation><mods:affiliation>Medizinische Abteilung, Krankenhaus der Barmherzigen Brüder Trier, Trier, Germany</mods:affiliation></affiliation></author><author><name sortKey="Botzenhardt, U" sort="Botzenhardt, U" uniqKey="Botzenhardt U" first="U." last="Botzenhardt">U. Botzenhardt</name><affiliation><mods:affiliation>Rheumatologische Abteilung, Rotes Kreuz-Krankenhaus Bremen, Bremen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Reemtsen, W" sort="Reemtsen, W" uniqKey="Reemtsen W" first="W." last="Reemtsen">W. Reemtsen</name><affiliation><mods:affiliation>Rheumatologische Abteilung, Rotes Kreuz-Krankenhaus Bremen, Bremen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Brackertz, D" sort="Brackertz, D" uniqKey="Brackertz D" first="D." last="Brackertz">D. Brackertz</name><affiliation><mods:affiliation>St. Vincenz- und Elisabeth-Hospital Mainz, Mainz, Germany</mods:affiliation></affiliation></author><author><name sortKey="Richter, D" sort="Richter, D" uniqKey="Richter D" first="D." last="Richter">D. Richter</name><affiliation><mods:affiliation>St. Vincenz- und Elisabeth-Hospital Mainz, Mainz, Germany</mods:affiliation></affiliation></author><author><name sortKey="Diehl, V" sort="Diehl, V" uniqKey="Diehl V" first="V." last="Diehl">V. Diehl</name><affiliation><mods:affiliation>Medizinische Universitätsklinik Köln, Koln, Germany</mods:affiliation></affiliation></author><author><name sortKey="Von Kalle, A K" sort="Von Kalle, A K" uniqKey="Von Kalle A" first="A. K." last="Von Kalle">A. K. Von Kalle</name><affiliation><mods:affiliation>Medizinische Universitätsklinik Köln, Koln, Germany</mods:affiliation></affiliation></author><author><name sortKey="G Rtner, C" sort="G Rtner, C" uniqKey="G Rtner C" first="C." last="G Rtner">C. G Rtner</name><affiliation><mods:affiliation>Krankenhaus Porz/Rhein, Abteilung Rheumatologie, Köln</mods:affiliation></affiliation></author><author><name sortKey="Herzig, S" sort="Herzig, S" uniqKey="Herzig S" first="S." last="Herzig">S. Herzig</name><affiliation><mods:affiliation>Krankenhaus Porz/Rhein, Abteilung Rheumatologie, Köln</mods:affiliation></affiliation></author><author><name sortKey="Goronzy, J" sort="Goronzy, J" uniqKey="Goronzy J" first="J." last="Goronzy">J. Goronzy</name><affiliation><mods:affiliation>Medizinische Poliklinik V Heidelberg, Heidelberg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Weyand, C" sort="Weyand, C" uniqKey="Weyand C" first="C." last="Weyand">C. Weyand</name><affiliation><mods:affiliation>Medizinische Poliklinik V Heidelberg, Heidelberg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Kalden, J R" sort="Kalden, J R" uniqKey="Kalden J" first="J. R." last="Kalden">J. R. Kalden</name><affiliation><mods:affiliation>Medizinische Klinik III und Institut für klinische Immunologie und Rheumatologie Erlangen, Erlangen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Strobel, F" sort="Strobel, F" uniqKey="Strobel F" first="F." last="Strobel">F. Strobel</name><affiliation><mods:affiliation>Medizinische Klinik III und Institut für klinische Immunologie und Rheumatologie Erlangen, Erlangen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Machalke, K" sort="Machalke, K" uniqKey="Machalke K" first="K." last="Machalke">K. Machalke</name><affiliation><mods:affiliation>Klinik Lippe, Horn-Bad Meinberg</mods:affiliation></affiliation></author><author><name sortKey="Peter, H H" sort="Peter, H H" uniqKey="Peter H" first="H. H." last="Peter">H. H. Peter</name><affiliation><mods:affiliation>Abteilung Rheumatologie und klinische Immunologie, Medizinische Universitätsklinik Freiburg, Freiburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Meske, S" sort="Meske, S" uniqKey="Meske S" first="S." last="Meske">S. Meske</name><affiliation><mods:affiliation>Abteilung Rheumatologie und klinische Immunologie, Medizinische Universitätsklinik Freiburg, Freiburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Schattenkirchner, M" sort="Schattenkirchner, M" uniqKey="Schattenkirchner M" first="M." last="Schattenkirchner">M. Schattenkirchner</name><affiliation><mods:affiliation>Rheumaeinheit, Medizinische Poliklinik der Universität München, Munchen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Kruger, K" sort="Kruger, K" uniqKey="Kruger K" first="K." last="Krüger">K. Krüger</name><affiliation><mods:affiliation>Rheumaeinheit, Medizinische Poliklinik der Universität München, Munchen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Sprekeler, R" sort="Sprekeler, R" uniqKey="Sprekeler R" first="R." last="Sprekeler">R. Sprekeler</name><affiliation><mods:affiliation>Diakoniekrankenhaus Rotenburg/Wümme, Rotenburg/Wümme, Germany</mods:affiliation></affiliation></author><author><name sortKey="Waller, H D" sort="Waller, H D" uniqKey="Waller H" first="H. D." last="Waller">H. D. Waller</name><affiliation><mods:affiliation>Abteilung Innere Medizin II, Medizinische Klinik Tübingen, Tubingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Saal, J G" sort="Saal, J G" uniqKey="Saal J" first="J. G." last="Saal">J. G. Saal</name><affiliation><mods:affiliation>Abteilung Innere Medizin II, Medizinische Klinik Tübingen, Tubingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Warnatz, H" sort="Warnatz, H" uniqKey="Warnatz H" first="H." last="Warnatz">H. Warnatz</name><affiliation><mods:affiliation>Katholisches Krankenhaus Essen-Werden, Essen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Lemm, G" sort="Lemm, G" uniqKey="Lemm G" first="G." last="Lemm">G. Lemm</name><affiliation><mods:affiliation>Katholisches Krankenhaus Essen-Werden, Essen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Wilms, K" sort="Wilms, K" uniqKey="Wilms K" first="K." last="Wilms">K. Wilms</name><affiliation><mods:affiliation>Medizinische Poliklinik der Universität Würzburg, Wurzburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Stolzenburg, T" sort="Stolzenburg, T" uniqKey="Stolzenburg T" first="T." last="Stolzenburg">T. Stolzenburg</name><affiliation><mods:affiliation>Medizinische Poliklinik der Universität Würzburg, Wurzburg, Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Rheumatology International</title><title level="j" type="sub">Clinical and Experimental Investigations</title><title level="j" type="abbrev">Rheumatol Int</title><idno type="ISSN">0172-8172</idno><idno type="eISSN">1437-160X</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="1992-11-01">1992-11-01</date><biblScope unit="volume">12</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="175">175</biblScope><biblScope unit="page" to="185">185</biblScope></imprint><idno type="ISSN">0172-8172</idno></series><idno type="istex">9D6BE8ED959279DE45398098C485ED3D9FAE729C</idno><idno type="DOI">10.1007/BF00302149</idno><idno type="ArticleID">BF00302149</idno><idno type="ArticleID">Art3</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0172-8172</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: The controlled clinical trial reported here is part of a multicenter clinical and basic research project, sponsored by the German Federal Minister of Science and Technology, directed by a standing commission of the president of the Max-Planck-Gesellschaft, and coordinated by the Max-Planck-Institut für Biochemie, München. Overall, 249 patients with rheumatoid arthritis (RA) were enrolled by 16 participating hospitals. In addition to NSAID treatment, patients were randomly given either interferon gamma (IFN-γ) or placebo. In the IFN-γ group, 107 patients were evaluated and in the control group, 116 patients were evaluated. The response rate after 3 months of treatment, according to joint pain indexes, was significantly higher in the IFN-γ group with an error probability of 1%. IFN-γ was able to reduce the quantity of corticosteroids administered. Compared with the control group, the IFN-γ group benefited considering all parameters measured. Most important side effects were transient fever and transient influenza-like symptoms; all other adverse events were comparable in both groups.</div></front></TEI><istex><corpusName>springer</corpusName><author><json:item><name>P. H. Hofschneider</name><affiliations><json:string>Max-Planck-Institut für Biochemie, Martinsried</json:string></affiliations></json:item><json:item><name>U. Winter</name><affiliations><json:string>Max-Planck-Institut für Biochemie, Martinsried</json:string></affiliations></json:item><json:item><name>E. -M. Lemmel</name><affiliations><json:string>Staatliches Rheumakrankenhaus Baden-Baden, Baden Baden, Germany</json:string></affiliations></json:item><json:item><name>B. Brölz</name><affiliations><json:string>Staatliches Rheumakrankenhaus Baden-Baden, Baden Baden, Germany</json:string></affiliations></json:item><json:item><name>W. Gaus</name><affiliations><json:string>Universität Ulm, Ulm, Germany</json:string></affiliations></json:item><json:item><name>S. Schmid</name><affiliations><json:string>Universität Ulm, Ulm, Germany</json:string></affiliations></json:item><json:item><name>H. -J. Obert</name><affiliations><json:string>Bioferon biochemische Substanzen GmbH & Co., Laupheim</json:string></affiliations></json:item><json:item><name>C. Stetter</name><affiliations><json:string>Bioferon biochemische Substanzen GmbH & Co., Laupheim</json:string></affiliations></json:item><json:item><name>I. O. Auer</name><affiliations><json:string>Medizinische Universitätsklinik, Luitpoldkrankenhaus, Würzburg</json:string></affiliations></json:item><json:item><name>C. Papst</name><affiliations><json:string>Medizinische Universitätsklinik, Luitpoldkrankenhaus, Würzburg</json:string></affiliations></json:item><json:item><name>W. H. Boesken</name><affiliations><json:string>Medizinische Abteilung, Krankenhaus der Barmherzigen Brüder Trier, Trier, Germany</json:string></affiliations></json:item><json:item><name>H. E. Stierle II</name><affiliations><json:string>Medizinische Abteilung, Krankenhaus der Barmherzigen Brüder Trier, Trier, Germany</json:string></affiliations></json:item><json:item><name>U. Botzenhardt</name><affiliations><json:string>Rheumatologische Abteilung, Rotes Kreuz-Krankenhaus Bremen, Bremen, Germany</json:string></affiliations></json:item><json:item><name>W. Reemtsen</name><affiliations><json:string>Rheumatologische Abteilung, Rotes Kreuz-Krankenhaus Bremen, Bremen, Germany</json:string></affiliations></json:item><json:item><name>D. Brackertz</name><affiliations><json:string>St. Vincenz- und Elisabeth-Hospital Mainz, Mainz, Germany</json:string></affiliations></json:item><json:item><name>D. Richter</name><affiliations><json:string>St. Vincenz- und Elisabeth-Hospital Mainz, Mainz, Germany</json:string></affiliations></json:item><json:item><name>V. Diehl</name><affiliations><json:string>Medizinische Universitätsklinik Köln, Koln, Germany</json:string></affiliations></json:item><json:item><name>A. K. von Kalle</name><affiliations><json:string>Medizinische Universitätsklinik Köln, Koln, Germany</json:string></affiliations></json:item><json:item><name>C. Gärtner</name><affiliations><json:string>Krankenhaus Porz/Rhein, Abteilung Rheumatologie, Köln</json:string></affiliations></json:item><json:item><name>S. Herzig</name><affiliations><json:string>Krankenhaus Porz/Rhein, Abteilung Rheumatologie, Köln</json:string></affiliations></json:item><json:item><name>J. Goronzy</name><affiliations><json:string>Medizinische Poliklinik V Heidelberg, Heidelberg, Germany</json:string></affiliations></json:item><json:item><name>C. Weyand</name><affiliations><json:string>Medizinische Poliklinik V Heidelberg, Heidelberg, Germany</json:string></affiliations></json:item><json:item><name>J. R. Kalden</name><affiliations><json:string>Medizinische Klinik III und Institut für klinische Immunologie und Rheumatologie Erlangen, Erlangen, Germany</json:string></affiliations></json:item><json:item><name>F. Strobel</name><affiliations><json:string>Medizinische Klinik III und Institut für klinische Immunologie und Rheumatologie Erlangen, Erlangen, Germany</json:string></affiliations></json:item><json:item><name>K. Machalke</name><affiliations><json:string>Klinik Lippe, Horn-Bad Meinberg</json:string></affiliations></json:item><json:item><name>H. H. Peter</name><affiliations><json:string>Abteilung Rheumatologie und klinische Immunologie, Medizinische Universitätsklinik Freiburg, Freiburg, Germany</json:string></affiliations></json:item><json:item><name>S. Meske</name><affiliations><json:string>Abteilung Rheumatologie und klinische Immunologie, Medizinische Universitätsklinik Freiburg, Freiburg, Germany</json:string></affiliations></json:item><json:item><name>M. Schattenkirchner</name><affiliations><json:string>Rheumaeinheit, Medizinische Poliklinik der Universität München, Munchen, Germany</json:string></affiliations></json:item><json:item><name>K. Krüger</name><affiliations><json:string>Rheumaeinheit, Medizinische Poliklinik der Universität München, Munchen, Germany</json:string></affiliations></json:item><json:item><name>R. Sprekeler</name><affiliations><json:string>Diakoniekrankenhaus Rotenburg/Wümme, Rotenburg/Wümme, Germany</json:string></affiliations></json:item><json:item><name>H. D. Waller</name><affiliations><json:string>Abteilung Innere Medizin II, Medizinische Klinik Tübingen, Tubingen, Germany</json:string></affiliations></json:item><json:item><name>J. G. Saal</name><affiliations><json:string>Abteilung Innere Medizin II, Medizinische Klinik Tübingen, Tubingen, Germany</json:string></affiliations></json:item><json:item><name>H. Warnatz</name><affiliations><json:string>Katholisches Krankenhaus Essen-Werden, Essen, Germany</json:string></affiliations></json:item><json:item><name>G. Lemm</name><affiliations><json:string>Katholisches Krankenhaus Essen-Werden, Essen, Germany</json:string></affiliations></json:item><json:item><name>K. Wilms</name><affiliations><json:string>Medizinische Poliklinik der Universität Würzburg, Wurzburg, Germany</json:string></affiliations></json:item><json:item><name>T. Stolzenburg</name><affiliations><json:string>Medizinische Poliklinik der Universität Würzburg, Wurzburg, Germany</json:string></affiliations></json:item></author><articleId><json:string>BF00302149</json:string><json:string>Art3</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>OriginalPaper</json:string></originalGenre><abstract>Summary: The controlled clinical trial reported here is part of a multicenter clinical and basic research project, sponsored by the German Federal Minister of Science and Technology, directed by a standing commission of the president of the Max-Planck-Gesellschaft, and coordinated by the Max-Planck-Institut für Biochemie, München. Overall, 249 patients with rheumatoid arthritis (RA) were enrolled by 16 participating hospitals. In addition to NSAID treatment, patients were randomly given either interferon gamma (IFN-γ) or placebo. In the IFN-γ group, 107 patients were evaluated and in the control group, 116 patients were evaluated. The response rate after 3 months of treatment, according to joint pain indexes, was significantly higher in the IFN-γ group with an error probability of 1%. IFN-γ was able to reduce the quantity of corticosteroids administered. Compared with the control group, the IFN-γ group benefited considering all parameters measured. Most important side effects were transient fever and transient influenza-like symptoms; all other adverse events were comparable in both groups.</abstract><qualityIndicators><score>6.92</score><pdfVersion>1.3</pdfVersion><pdfPageSize>597.28 x 785 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1107</abstractCharCount><pdfWordCount>8643</pdfWordCount><pdfCharCount>45922</pdfCharCount><pdfPageCount>11</pdfPageCount><abstractWordCount>160</abstractWordCount></qualityIndicators><title>Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis</title><corporate><json:item><name>German Lymphokine Study Group</name></json:item></corporate><refBibs><json:item><author><json:item><name>P,H Hofschneider</name></json:item><json:item><name>U Winter</name></json:item></author><host><author></author><title>Institut fiir Biochemie, Martinsried E.-M. Lemmel, B. Br61z, Staatliches Rheumakrankenhaus Baden- Baden</title></host></json:item><json:item><host><author><json:item><name>W Gaus</name></json:item><json:item><name>S Schmid</name></json:item></author></host></json:item><json:item><author><json:item><name>H.-J Obert</name></json:item><json:item><name>C Stetter</name></json:item><json:item><name>& Bioferon Biochemische Substanzen Gmbh</name></json:item><json:item><name>Laupheim Co</name></json:item><json:item><name>Clinicians,I O Hospitals</name></json:item><json:item><name>C Auer</name></json:item><json:item><name>Medizinische Papst</name></json:item><json:item><name> Universits</name></json:item><json:item><name>Luitpoldkrankenhaus Tsklinik</name></json:item><json:item><name>W,H Wfirzburg</name></json:item><json:item><name>H,E Boesken</name></json:item><json:item><name>Ii Stierle</name></json:item><json:item><name> Medizinische Abteilung</name></json:item><json:item><name> Krankenhaus Der Barmherzigen Brfider</name></json:item><json:item><name>U Trier</name></json:item><json:item><name>W Botzenhardt</name></json:item><json:item><name>Rheumatologische,Abteilung Reemtsen</name></json:item><json:item><name>D Brackertz</name></json:item><json:item><name> Richter</name></json:item><json:item><name> St</name></json:item><json:item><name>Elisabeth-Hospital Vincenz-Und</name></json:item><json:item><name>V Mainz</name></json:item><json:item><name>A,K Diehl</name></json:item><json:item><name>Medizinische Kalle</name></json:item><json:item><name>/ Universit</name></json:item><json:item><name>C Itsklinik K61n</name></json:item><json:item><name>S G / Irtner</name></json:item><json:item><name>Abteilung Herzig</name></json:item><json:item><name>Krankenhaus Rheumatologie</name></json:item><json:item><name>/ Porz</name></json:item><json:item><name>K61n,J Rhein</name></json:item><json:item><name>C Goronzy</name></json:item><json:item><name>Medizinische Weyand</name></json:item><json:item><name>V Poliklinik</name></json:item><json:item><name>J,R Heidelberg</name></json:item><json:item><name>F Kalden</name></json:item><json:item><name> Strobel</name></json:item></author><host><author></author><title>Medizinische Klinik III und Institut ffir klinische Immunologic und Rheumatologie Erlangen E.-M. Lemmel Abteilung Inhere Medizin II</title></host></json:item><json:item><author><json:item><name>Em Lemmel</name></json:item><json:item><name>Gl Bach</name></json:item><json:item><name>W Bolten</name></json:item><json:item><name>D Brackertz</name></json:item><json:item><name>Z Fahmy</name></json:item><json:item><name>H Mattern</name></json:item><json:item><name>I Stroehmann</name></json:item><json:item><name>A Wittenborg</name></json:item></author><host><volume>113</volume><pages><last>176</last><first>172</first></pages><author></author><title>Dtsch Med Wochenschr</title><publicationDate>1988</publicationDate></host><title>Immunmodulierende Therapie der chronischen Polyarthritis mit Thymopentin . Eine multizentrische placebokontrollierte Studie an 119 Patienten</title><publicationDate>1988</publicationDate></json:item><json:item><author><json:item><name>Ca Dinarello</name></json:item><json:item><name>Jw Mier</name></json:item></author><host><volume>317</volume><pages><last>945</last><first>940</first></pages><author></author><title>N Engl J Med</title><publicationDate>1987</publicationDate></host><title>Lymphokines</title><publicationDate>1987</publicationDate></json:item><json:item><author><json:item><name>G Gastl</name></json:item><json:item><name>C Huber</name></json:item></author><host><volume>56</volume><pages><last>199</last><first>193</first></pages><author></author><title>Blut</title><publicationDate>1988</publicationDate></host><title>The biology of interferon actions</title><publicationDate>1988</publicationDate></json:item><json:item><author><json:item><name>H Ieremans</name></json:item><json:item><name>A Billiau</name></json:item></author><host><volume>38</volume><pages><last>972</last><first>957</first></pages><author></author><title>Drugs</title><publicationDate>1989</publicationDate></host><title>The potential role of interferons and interferon antagonists in inflammatory disease</title><publicationDate>1989</publicationDate></json:item><json:item><host><pages><last>391</last><first>379</first></pages><author><json:item><name>J Brzoska</name></json:item><json:item><name>Hj Obert</name></json:item></author><title>Immunomodulating effects of interferons: conclusions for therapy Genital papillomavirus infections: modern diagnosis and treatment</title><publicationDate>1990</publicationDate></host></json:item><json:item><author><json:item><name>J Brzoska</name></json:item><json:item><name>Hj Obert</name></json:item></author><host><volume>37</volume><pages><last>1416</last><first>1410</first></pages><author></author><title>Arzneimittelforschung/ Drug Res</title><publicationDate>1987</publicationDate></host><title>Interferon gamma: ein janus- k6pfiger Mediator bet Entziindungen</title><publicationDate>1987</publicationDate></json:item><json:item><author><json:item><name>Ca Dinarello</name></json:item></author><host><volume>2</volume><pages><last>115</last><first>108</first></pages><author></author><title>FASEB J</title><publicationDate>1988</publicationDate></host><title>Biology ofinterleukin-l</title><publicationDate>1988</publicationDate></json:item><json:item><author><json:item><name>Lc Miller</name></json:item><json:item><name>Ca Dinarello</name></json:item></author><host><volume>6</volume><pages><last>36</last><first>22</first></pages><author></author><title>Pathol Immunopathol Res</title><publicationDate>1987</publicationDate></host><title>Biologic activities of inter- leukin-1 relevant to rheumatic diseases</title><publicationDate>1987</publicationDate></json:item><json:item><author><json:item><name>N Miyasaka</name></json:item><json:item><name>K Sato</name></json:item><json:item><name>M Goto</name></json:item><json:item><name>M Sasano</name></json:item><json:item><name>M Natsuyama</name></json:item><json:item><name>K Inoue</name></json:item><json:item><name>K Nishioka</name></json:item></author><host><volume>31</volume><pages><last>486</last><first>480</first></pages><author></author><title>Arthritis Rheum</title><publicationDate>1988</publicationDate></host><title>Augmented interleukin-i production and HLA-DR expression in the synovium of rheumatoid arthritis patients. Possible involvement in joint destruction</title><publicationDate>1988</publicationDate></json:item><json:item><author><json:item><name>B Koch</name></json:item><json:item><name>W Baum</name></json:item><json:item><name>Gr Burmester</name></json:item><json:item><name>P Rohwer</name></json:item><json:item><name>M Reinke</name></json:item><json:item><name>J Zacher</name></json:item><json:item><name>H Kirchner</name></json:item><json:item><name>Jr Kalden</name></json:item></author><host><volume>48</volume><pages><last>199</last><first>194</first></pages><author></author><title>Z Rheumatol</title><publicationDate>1989</publicationDate></host><title>Prostaglandin-E2-, Inter- leukin-1-und Interferon-Gamma-Produktion mononukle</title><publicationDate>1989</publicationDate></json:item><json:item><author><json:item><name>Jb Smith</name></json:item><json:item><name>Mh Bocchieri</name></json:item><json:item><name>L Sherbin-Allen</name></json:item><json:item><name>M Borofsky</name></json:item><json:item><name>Jl Abruzzo</name></json:item></author><host><volume>9</volume><pages><last>58</last><first>53</first></pages><author></author><title>Rheumatol Int</title><publicationDate>1989</publicationDate></host><title>Occurrence of interleukin-I in human synovial fluid: detection by RIA, bioassay and presence of bioassay-inhibiting factors</title><publicationDate>1989</publicationDate></json:item><json:item><author><json:item><name>K Bendtzen</name></json:item><json:item><name>J Petersen</name></json:item><json:item><name>J Halkjrer-Kristensen</name></json:item><json:item><name>T Ingemann-Hansen</name></json:item></author><host><volume>5</volume><pages><last>82</last><first>79</first></pages><author></author><title>Rheumatol Int</title><publicationDate>1985</publicationDate></host><title>Interleukin-1 like activities in synovial fluids of patients with rheumatoid arthritis and traumatic synovitis</title><publicationDate>1985</publicationDate></json:item><json:item><author><json:item><name>E Hermann</name></json:item><json:item><name>P Vogt</name></json:item><json:item><name>W Hagmann</name></json:item><json:item><name>A Dunky</name></json:item><json:item><name>W Mfiller</name></json:item></author><host><volume>47</volume><pages><last>25</last><first>20</first></pages><author></author><title>Z Rheumatol Int</title><publicationDate>1988</publicationDate></host><title>Synoviaspiegel yon Interleukin-I und C3a bet chronischer Polyarthritis, Psoriasisarthritis und aktivierter Arthrose</title><publicationDate>1988</publicationDate></json:item><json:item><author><json:item><name>Va Danis</name></json:item><json:item><name>A,J Kulesz</name></json:item><json:item><name>Ds Nelson</name></json:item><json:item><name>Pm Brooks</name></json:item></author><host><volume>80</volume><pages><last>443</last><first>435</first></pages><author></author><title>Clin Exp Immunol</title><publicationDate>1990</publicationDate></host><title>Cytokine regulation of human monocyte interleukin-1 (IL-1) production in vitro. Enhancement of IL-1 production by interferon (IFN) gamma, tumour necrosis factor-alpha, IL-2 und IL-1, and inhibition by IFN-alpha</title><publicationDate>1990</publicationDate></json:item><json:item><author><json:item><name>Wj Johnson</name></json:item><json:item><name>J Breton</name></json:item><json:item><name>T Newman-Tarr</name></json:item><json:item><name>Jr Connor</name></json:item><json:item><name>Pc Meunier</name></json:item><json:item><name>Bj Dalton</name></json:item></author><host><volume>33</volume><pages><last>267</last><first>261</first></pages><author></author><title>Arthritis Rheum</title><publicationDate>1990</publicationDate></host><title>Interleukin-1 release by rat synovial cells is dependent on sequential treatment with 7-interferon and lipopolysaccharide</title><publicationDate>1990</publicationDate></json:item><json:item><author><json:item><name>M Harth</name></json:item><json:item><name>Ga Mccain</name></json:item><json:item><name>K Cousin</name></json:item></author><host><volume>20</volume><pages><last>134</last><first>125</first></pages><author></author><title>Immunopharmacology</title><publicationDate>1990</publicationDate></host><title>The modulation of interleukin-1 production by interferon gamma, and the inhibitory effects of gold compounds</title><publicationDate>1990</publicationDate></json:item><json:item><author><json:item><name>Sr Brandwein</name></json:item></author><host><volume>261</volume><pages><last>8632</last><first>8624</first></pages><author></author><title>J Biol Chem</title><publicationDate>1986</publicationDate></host><title>Regulation of interleukin-1 production by mouse peritoneal macrophages</title><publicationDate>1986</publicationDate></json:item><json:item><author><json:item><name>Fm Rowe</name></json:item><json:item><name>J Edwards</name></json:item><json:item><name>Pj Cozens</name></json:item></author><host><volume>42</volume><pages><last>601</last><first>600</first></pages><author></author><title>J Leukocyte Biol</title><publicationDate>1987</publicationDate></host><title>Increased interleukin-1 levels from monocytes of rheumatoid arthritis patients during the early stages of the disease are down regulated in vitro by the addition of interferon-gamma</title><publicationDate>1987</publicationDate></json:item><json:item><author><json:item><name>S Ruschen</name></json:item><json:item><name>G Lemm</name></json:item><json:item><name>H Warnatz</name></json:item></author><host><volume>76</volume><pages><last>251</last><first>246</first></pages><author></author><title>Clin Exp Immunol</title><publicationDate>1989</publicationDate></host><title>Spontaneous and LPS-stimutated production of intracellular IL-lfl by synoviai macrophages in rheumatoid arthritis is inhibited by IFN%</title><publicationDate>1989</publicationDate></json:item><json:item><author><json:item><name>P Ghezzi</name></json:item><json:item><name>Ca Dinarello</name></json:item></author><host><volume>140</volume><pages><last>4244</last><first>4238</first></pages><author></author><title>J Immunol</title><publicationDate>1988</publicationDate></host><title>IL-I induces IL-I. III. Specific inhibition of IL-I production by IFN-y</title><publicationDate>1988</publicationDate></json:item><json:item><author><json:item><name>Gs Firestein</name></json:item><json:item><name>Nj Zvaifler</name></json:item></author><host><volume>30</volume><pages><last>871</last><first>864</first></pages><author></author><title>Arthritis Rheum</title><publicationDate>1987</publicationDate></host><title>Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that 7-interferon is not the primary macrophage activating factor</title><publicationDate>1987</publicationDate></json:item><json:item><author><json:item><name>M Ridley</name></json:item><json:item><name>G Panayi</name></json:item></author><host><volume>31</volume><pages><first>1209</first></pages><author></author><title>Arthritis Rheum</title><publicationDate>1988</publicationDate></host><title>Comment on the articles by Firestein and Zvaifler</title><publicationDate>1988</publicationDate></json:item><json:item><author><json:item><name>G Buchan</name></json:item><json:item><name>K Barrett</name></json:item><json:item><name>T Fujita</name></json:item><json:item><name>T Taniguchi</name></json:item><json:item><name>R Maini</name></json:item><json:item><name>M Feldmann</name></json:item></author><host><volume>71</volume><pages><last>401</last><first>395</first></pages><author></author><title>Clin Exp Immunol</title><publicationDate>1988</publicationDate></host><title>Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-~</title><publicationDate>1988</publicationDate></json:item><json:item><author><json:item><name>Sj Hopkins</name></json:item><json:item><name>A Meager</name></json:item></author><host><volume>73</volume><pages><last>92</last><first>88</first></pages><author></author><title>Clin Exp Immunol</title><publicationDate>1988</publicationDate></host><title>Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon</title><publicationDate>1988</publicationDate></json:item><json:item><author><json:item><name>Gs Firestein</name></json:item><json:item><name>Jm Alvaro-Garcia</name></json:item><json:item><name>R Maki</name></json:item></author><host><volume>144</volume><pages><last>3353</last><first>3347</first></pages><author></author><title>J Immunol</title><publicationDate>1990</publicationDate></host><title>Quantitative analysis of cytokine gene expression in rheumatoid arthritis</title><publicationDate>1990</publicationDate></json:item><json:item><author><json:item><name>Em Lemmei</name></json:item><json:item><name>M Franke</name></json:item><json:item><name>W Gaus</name></json:item><json:item><name>Pw Hartl</name></json:item><json:item><name>Ph Hofschneider</name></json:item><json:item><name>K Miehlke</name></json:item><json:item><name>K Machalke</name></json:item><json:item><name>Hj Obert</name></json:item></author><host><volume>7</volume><pages><last>132</last><first>127</first></pages><author></author><title>Rheumatol Int</title><publicationDate>1987</publicationDate></host><title>Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma</title><publicationDate>1987</publicationDate></json:item><json:item><author><json:item><name>A Zilly</name></json:item><json:item><name>Hj Obert</name></json:item></author><host><volume>128</volume><pages><last>89</last><first>87</first></pages><author></author><title>Ergebnisse einer Pilot-Studie mit Lymphokinen. MMW</title><publicationDate>1986</publicationDate></host><title>Therapie der chronischen Polyarthritis</title><publicationDate>1986</publicationDate></json:item><json:item><author><json:item><name>F Wolfe</name></json:item><json:item><name>Ma Cathey</name></json:item><json:item><name>D,J Hawley</name></json:item><json:item><name>Jp Balser</name></json:item><json:item><name>Jd Schindler</name></json:item></author><host><pages><last>395</last><first>379</first></pages><author></author><title>Biologically based immunomodulators in the therapy of rheumatic diseases</title><publicationDate>1986</publicationDate></host><title>Clinical trial with r-IFN-gamma in rheumatoid arthritis</title><publicationDate>1986</publicationDate></json:item><json:item><author><json:item><name>Em Lemmel</name></json:item><json:item><name>D Brackertz</name></json:item><json:item><name>M Franke</name></json:item><json:item><name>W Gaus</name></json:item><json:item><name>Pw Hartl</name></json:item><json:item><name>K Machalke</name></json:item><json:item><name>H Mielke</name></json:item><json:item><name>H,J Obert</name></json:item><json:item><name>Hh Peter</name></json:item><json:item><name>J Sieper</name></json:item><json:item><name>R Sprekeler</name></json:item><json:item><name>H Stierle</name></json:item></author><host><volume>8</volume><pages><last>93</last><first>87</first></pages><author></author><title>Rheumatol Int</title><publicationDate>1988</publicationDate></host><title>Results of a multicenter placebocontrolled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma</title><publicationDate>1988</publicationDate></json:item><json:item><author><json:item><name>Em Lemmel</name></json:item><json:item><name>Hj Obert</name></json:item><json:item><name>Ph Iofschneider</name></json:item></author><host><volume>I</volume><pages><first>598</first></pages><author></author><title>Lancet</title><publicationDate>1988</publicationDate></host><title>Low-dose gamma interferon treatment of rheumatoid arthritis</title><publicationDate>1988</publicationDate></json:item><json:item><author><json:item><name>Gw Cannon</name></json:item><json:item><name>Jd Schindler</name></json:item><json:item><name>Rd Emkey</name></json:item><json:item><name>A Denes</name></json:item><json:item><name>Sa Cohen</name></json:item><json:item><name>F Wolfe</name></json:item><json:item><name>A Saway</name></json:item><json:item><name>Am Jaffer</name></json:item><json:item><name>Al Weaver</name></json:item><json:item><name>L Cogen</name></json:item></author><host><volume>30</volume><pages><first>18</first></pages><author></author><title>Arthritis Rheum</title><publicationDate>1987</publicationDate></host><title>Double-blind trial of recombinant interferon-gamma versus placebo in rheumatoid arthritis</title><publicationDate>1987</publicationDate></json:item><json:item><author><json:item><name>Em Veys</name></json:item><json:item><name>H Mielants</name></json:item><json:item><name>G Verbruggen</name></json:item><json:item><name>Jp Grosclaude</name></json:item><json:item><name>F Luyten</name></json:item><json:item><name>W Meier</name></json:item><json:item><name>W Fiers</name></json:item><json:item><name>Ar Galazka</name></json:item></author><host><volume>5</volume><pages><first>53</first></pages><author></author><title>Clin Exp Rheumatol</title><publicationDate>1987</publicationDate></host><title>Recombinant interferon gamma in rheumatoid arthritis. A double-blind study comparing Immuneron (recombinant interferon gamma) with placebo</title><publicationDate>1987</publicationDate></json:item><json:item><author><json:item><name>H,J Obert</name></json:item><json:item><name>Jf Brzoska</name></json:item></author><host><volume>39</volume><pages><last>822</last><first>819</first></pages><author></author><title>Arzneimittelforschung/Drug Res</title><publicationDate>1989</publicationDate></host><title>Interferon gamma in der Therapie der chronischen Polyarthritis. Die Langzeitbehandlung in der Praxis</title><publicationDate>1989</publicationDate></json:item><json:item><author><json:item><name>Ho Klein</name></json:item></author><host><volume>106</volume><pages><last>725</last><first>721</first></pages><author></author><title>Fortschr Med</title><publicationDate>1988</publicationDate></host><title>Therapie der rheumatoiden Arthritis mit rekombinantem Interferon-gamma</title><publicationDate>1988</publicationDate></json:item><json:item><author><json:item><name>R Sprekeler</name></json:item><json:item><name>Em Lemmel</name></json:item><json:item><name>Hj Obert</name></json:item></author><host><volume>49</volume><pages><last>7</last><first>1</first></pages><author></author><title>Z Rheumatol</title><publicationDate>1990</publicationDate></host><title>Correlation of clinical and serological findings in patients with rheumatoid arthritis treated for one year with interferon-gamma</title><publicationDate>1990</publicationDate></json:item><json:item><author><json:item><name>Gw Cannon</name></json:item><json:item><name>Rd Emkey</name></json:item><json:item><name>A Denes</name></json:item><json:item><name>Sa Cohen</name></json:item><json:item><name>Pa Saway</name></json:item><json:item><name>F Wolfe</name></json:item><json:item><name>Am Jaffer</name></json:item><json:item><name>Al Weaver</name></json:item><json:item><name>L Cogen</name></json:item><json:item><name>J Guiinello</name></json:item><json:item><name>Sm Kennedy</name></json:item><json:item><name>Jd Schindler</name></json:item></author><host><pages><last>310</last><first>304</first></pages><author></author><title>J Rheumato117</title><publicationDate>1990</publicationDate></host><title>Prospective two-year followup of recombinant interferon-7 in rheumatoid arthritis</title><publicationDate>1990</publicationDate></json:item><json:item><author><json:item><name>Hj Obert</name></json:item><json:item><name>Jf Brzoska</name></json:item></author><host><volume>9</volume><pages><last>292</last><first>286</first></pages><author></author><title>Rheuma</title><publicationDate>1989</publicationDate></host><title>Behandlung der chronischen Polyarthritis mit Interferon-gamma. Ergebnisse einer Therapiestudie der Phase II bei 476 Patienten</title><publicationDate>1989</publicationDate></json:item><json:item><author><json:item><name>Y Taya</name></json:item><json:item><name>R Devos</name></json:item><json:item><name>J Tavernier</name></json:item><json:item><name>H Cheroutre</name></json:item><json:item><name>G Engler</name></json:item><json:item><name>W Fiers</name></json:item></author><host><volume>1</volume><pages><first>953</first></pages><author></author><title>EMBO J</title><publicationDate>1982</publicationDate></host><title>Cloning and structure of the human immune interferongamma chromosomal gene</title><publicationDate>1982</publicationDate></json:item><json:item><author><json:item><name>G Simons</name></json:item><json:item><name>E Remaut</name></json:item><json:item><name>B Allet</name></json:item><json:item><name>R Devos</name></json:item><json:item><name>W Fiers</name></json:item></author><host><volume>28</volume><pages><first>55</first></pages><author></author><title>Gene</title><publicationDate>1984</publicationDate></host><title>Highlevel expression of human interferon gamma in Escherichia coli under control of the PL promotor of bacteriophage lambda</title><publicationDate>1984</publicationDate></json:item><json:item><author><json:item><name>Pw Gray</name></json:item><json:item><name>Dv Goeddel</name></json:item></author><host><volume>298</volume><pages><last>863</last><first>859</first></pages><author></author><title>Nature</title><publicationDate>1982</publicationDate></host><title>Structure of the human immune interferon gene</title><publicationDate>1982</publicationDate></json:item><json:item><author><json:item><name>M Ropes</name></json:item><json:item><name>Ga Bennett</name></json:item><json:item><name>S Cobb</name></json:item><json:item><name>R Jacox</name></json:item><json:item><name>R Jessar</name></json:item></author><host><volume>9</volume><pages><last>176</last><first>175</first></pages><author></author><title>Bull Rheum Dis</title><publicationDate>1958</publicationDate></host><title>1958 revision of diagnostic criteria for rheumatoid arthritis</title><publicationDate>1958</publicationDate></json:item><json:item><author><json:item><name>Fc Arnett</name></json:item><json:item><name>Sm Edworthy</name></json:item><json:item><name>Da Bloch</name></json:item><json:item><name>Dj Mcshane</name></json:item><json:item><name>Jf Fries</name></json:item><json:item><name>Ns Cooper</name></json:item><json:item><name>La Healey</name></json:item><json:item><name>Sr Kaplan</name></json:item><json:item><name>Mh Liang</name></json:item><json:item><name>Hs Luthra</name></json:item><json:item><name>Ta Medsger</name></json:item><json:item><name>Dm Mitchell</name></json:item><json:item><name>Dh Neustadt</name></json:item></author><host><volume>31</volume><pages><last>323</last><first>315</first></pages><author></author><title>Arthritis Rheum</title><publicationDate>1988</publicationDate></host><title>The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis</title><publicationDate>1988</publicationDate></json:item><json:item><author><json:item><name>Dm Ritchie</name></json:item><json:item><name>Ja Boyle</name></json:item><json:item><name>Jm Mcinnes</name></json:item><json:item><name>Mk Jasani</name></json:item><json:item><name>Tg Dalakos</name></json:item><json:item><name>P Grieveson</name></json:item><json:item><name>Ww Buchanan</name></json:item></author><host><volume>37</volume><pages><last>406</last><first>393</first></pages><author></author><title>Q J Med</title><publicationDate>1968</publicationDate></host><title>Clinical studies with an 185 articular index for the assessment of joint tenderness in patients with rheumatoid arthritis</title><publicationDate>1968</publicationDate></json:item><json:item><author><json:item><name>J Lansbury</name></json:item></author><host><volume>1</volume><pages><last>522</last><first>505</first></pages><author></author><title>Arthritis Rheum</title><publicationDate>1958</publicationDate></host><title>Report of a three-year study on the systemic and articular indexes in rheumatoid arthritis. Theoretic and clinical considerations</title><publicationDate>1958</publicationDate></json:item><json:item><host><pages><last>291</last><first>269</first></pages><author><json:item><name>J Lansbury</name></json:item></author><title>Methods for evaluating rheumatoid arthritis Arthritis and allied conditions</title><publicationDate>1967</publicationDate></host></json:item><json:item><author><json:item><name>P Lee</name></json:item><json:item><name>Mk Jasani</name></json:item><json:item><name>Wc Dick</name></json:item><json:item><name>Ww Buchanan</name></json:item></author><host><volume>2</volume><pages><last>77</last><first>71</first></pages><author></author><title>Scand J Rheumatol</title><publicationDate>1973</publicationDate></host><title>Evaluation of a functional index in rheumatoid arthritis</title><publicationDate>1973</publicationDate></json:item><json:item><host><author><json:item><name>W Gaus</name></json:item></author><title>Contributions to robust estimation: trimmed variance and censored median. Presentation at the joint biometric conference of the German and British region</title><publicationDate>1991-03-19</publicationDate></host></json:item><json:item><author><json:item><name>Hj Obert</name></json:item><json:item><name>Ph Hofschneider</name></json:item></author><host><volume>110</volume><pages><last>1769</last><first>1766</first></pages><author></author><title>Dtsch Med Wochenschr</title><publicationDate>1985</publicationDate></host><title>Interferon bei chronischer Polyarthritis. Positive Wirkung in der klinischen Priifung</title><publicationDate>1985</publicationDate></json:item><json:item><author><json:item><name>Kp Machold</name></json:item><json:item><name>W Graninger</name></json:item><json:item><name>R Flener</name></json:item><json:item><name>Js Smolen</name></json:item></author><host><volume>36</volume><pages><first>534</first></pages><author></author><title>Clin Res</title><publicationDate>1988</publicationDate></host><title>Recombinant human gamma-interferon in the treatment of rheumatoid arthritis -a double-blind placebo-controlled crossover study</title><publicationDate>1988</publicationDate></json:item><json:item><author><json:item><name>A B6ni</name></json:item><json:item><name>Ph Hofsehneider</name></json:item><json:item><name>Hj Obert</name></json:item></author><host><volume>7</volume><pages><last>40</last><first>34</first></pages><author></author><title>Erste Ergebnisse mit Interferon-gamma. DIA-GM</title><publicationDate>1986</publicationDate></host><title>Chronische Polyarthritis</title><publicationDate>1986</publicationDate></json:item><json:item><author><json:item><name>Hj Obert</name></json:item><json:item><name>J Brzoska</name></json:item></author><host><volume>36</volume><pages><last>1560</last><first>1557</first></pages><author></author><title>Arzneimittelforschung/Drug Res</title><publicationDate>1986</publicationDate></host><title>Interferon-gamma in der Therapie der chronischen Polyarthritis</title><publicationDate>1986</publicationDate></json:item><json:item><author><json:item><name>Gw Cannon</name></json:item><json:item><name>Sh Pincus</name></json:item><json:item><name>Rd Emkey</name></json:item><json:item><name>A Denes</name></json:item><json:item><name>Sa Cohen</name></json:item><json:item><name>F Wolfe</name></json:item><json:item><name>Pa Saway</name></json:item><json:item><name>Am Jaffer</name></json:item><json:item><name>Al Weaver</name></json:item><json:item><name>L Cogen</name></json:item><json:item><name>Jd Schindler</name></json:item></author><host><volume>32</volume><pages><last>973</last><first>964</first></pages><author></author><title>Arthritis Rheum</title><publicationDate>1989</publicationDate></host><title>Double-blind trial of recombinant y-interferon versus placebo in the treatment of rheumatoid arthritis</title><publicationDate>1989</publicationDate></json:item></refBibs><genre><json:string>research-article</json:string></genre><host><volume>12</volume><pages><last>185</last><first>175</first></pages><issn><json:string>0172-8172</json:string></issn><issue>5</issue><subject><json:item><value>Rheumatology</value></json:item></subject><journalId><json:string>296</json:string></journalId><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1437-160X</json:string></eissn><title>Rheumatology International</title><publicationDate>1992</publicationDate><copyrightDate>1992</copyrightDate></host><categories><wos><json:string>science</json:string><json:string>rheumatology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>arthritis & rheumatology</json:string></scienceMetrix></categories><publicationDate>1992</publicationDate><copyrightDate>1992</copyrightDate><doi><json:string>10.1007/BF00302149</json:string></doi><id>9D6BE8ED959279DE45398098C485ED3D9FAE729C</id><score>0.21970318</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/9D6BE8ED959279DE45398098C485ED3D9FAE729C/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/9D6BE8ED959279DE45398098C485ED3D9FAE729C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/9D6BE8ED959279DE45398098C485ED3D9FAE729C/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><availability><p>Springer-Verlag, 1992</p></availability><date>1992-07-01</date></publicationStmt><notesStmt><note>Originals</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis</title><author><orgName>German Lymphokine Study Group</orgName></author><author xml:id="author-2"><persName><forename type="first">P.</forename><surname>Hofschneider</surname></persName><affiliation>Max-Planck-Institut für Biochemie, Martinsried</affiliation></author><author xml:id="author-3"><persName><forename type="first">U.</forename><surname>Winter</surname></persName><affiliation>Max-Planck-Institut für Biochemie, Martinsried</affiliation></author><author xml:id="author-4" corresp="yes"><persName><forename type="first">E.</forename><surname>Lemmel</surname></persName><affiliation>Staatliches Rheumakrankenhaus Baden-Baden, Baden Baden, Germany</affiliation></author><author xml:id="author-5"><persName><forename type="first">B.</forename><surname>Brölz</surname></persName><note type="biography">main investigator</note><affiliation>main investigator</affiliation><affiliation>Staatliches Rheumakrankenhaus Baden-Baden, Baden Baden, Germany</affiliation></author><author xml:id="author-6"><persName><forename type="first">W.</forename><surname>Gaus</surname></persName><affiliation>Universität Ulm, Ulm, Germany</affiliation></author><author xml:id="author-7"><persName><forename type="first">S.</forename><surname>Schmid</surname></persName><affiliation>Universität Ulm, Ulm, Germany</affiliation></author><author xml:id="author-8"><persName><forename type="first">H.</forename><surname>Obert</surname></persName><affiliation>Bioferon biochemische Substanzen GmbH & Co., Laupheim</affiliation></author><author xml:id="author-9"><persName><forename type="first">C.</forename><surname>Stetter</surname></persName><affiliation>Bioferon biochemische Substanzen GmbH & Co., Laupheim</affiliation></author><author xml:id="author-10"><persName><forename type="first">I.</forename><surname>Auer</surname></persName><affiliation>Medizinische Universitätsklinik, Luitpoldkrankenhaus, Würzburg</affiliation></author><author xml:id="author-11"><persName><forename type="first">C.</forename><surname>Papst</surname></persName><affiliation>Medizinische Universitätsklinik, Luitpoldkrankenhaus, Würzburg</affiliation></author><author xml:id="author-12"><persName><forename type="first">W.</forename><surname>Boesken</surname></persName><affiliation>Medizinische Abteilung, Krankenhaus der Barmherzigen Brüder Trier, Trier, Germany</affiliation></author><author xml:id="author-13"><persName><forename type="first">H.</forename><surname>Stierle II</surname></persName><affiliation>Medizinische Abteilung, Krankenhaus der Barmherzigen Brüder Trier, Trier, Germany</affiliation></author><author xml:id="author-14"><persName><forename type="first">U.</forename><surname>Botzenhardt</surname></persName><affiliation>Rheumatologische Abteilung, Rotes Kreuz-Krankenhaus Bremen, Bremen, Germany</affiliation></author><author xml:id="author-15"><persName><forename type="first">W.</forename><surname>Reemtsen</surname></persName><affiliation>Rheumatologische Abteilung, Rotes Kreuz-Krankenhaus Bremen, Bremen, Germany</affiliation></author><author xml:id="author-16"><persName><forename type="first">D.</forename><surname>Brackertz</surname></persName><affiliation>St. Vincenz- und Elisabeth-Hospital Mainz, Mainz, Germany</affiliation></author><author xml:id="author-17"><persName><forename type="first">D.</forename><surname>Richter</surname></persName><affiliation>St. Vincenz- und Elisabeth-Hospital Mainz, Mainz, Germany</affiliation></author><author xml:id="author-18"><persName><forename type="first">V.</forename><surname>Diehl</surname></persName><affiliation>Medizinische Universitätsklinik Köln, Koln, Germany</affiliation></author><author xml:id="author-19"><persName><forename type="first">A.</forename><surname>von Kalle</surname></persName><affiliation>Medizinische Universitätsklinik Köln, Koln, Germany</affiliation></author><author xml:id="author-20"><persName><forename type="first">C.</forename><surname>Gärtner</surname></persName><affiliation>Krankenhaus Porz/Rhein, Abteilung Rheumatologie, Köln</affiliation></author><author xml:id="author-21"><persName><forename type="first">S.</forename><surname>Herzig</surname></persName><affiliation>Krankenhaus Porz/Rhein, Abteilung Rheumatologie, Köln</affiliation></author><author xml:id="author-22"><persName><forename type="first">J.</forename><surname>Goronzy</surname></persName><affiliation>Medizinische Poliklinik V Heidelberg, Heidelberg, Germany</affiliation></author><author xml:id="author-23"><persName><forename type="first">C.</forename><surname>Weyand</surname></persName><affiliation>Medizinische Poliklinik V Heidelberg, Heidelberg, Germany</affiliation></author><author xml:id="author-24"><persName><forename type="first">J.</forename><surname>Kalden</surname></persName><affiliation>Medizinische Klinik III und Institut für klinische Immunologie und Rheumatologie Erlangen, Erlangen, Germany</affiliation></author><author xml:id="author-25"><persName><forename type="first">F.</forename><surname>Strobel</surname></persName><affiliation>Medizinische Klinik III und Institut für klinische Immunologie und Rheumatologie Erlangen, Erlangen, Germany</affiliation></author><author xml:id="author-26"><persName><forename type="first">K.</forename><surname>Machalke</surname></persName><affiliation>Klinik Lippe, Horn-Bad Meinberg</affiliation></author><author xml:id="author-27"><persName><forename type="first">H.</forename><surname>Peter</surname></persName><affiliation>Abteilung Rheumatologie und klinische Immunologie, Medizinische Universitätsklinik Freiburg, Freiburg, Germany</affiliation></author><author xml:id="author-28"><persName><forename type="first">S.</forename><surname>Meske</surname></persName><affiliation>Abteilung Rheumatologie und klinische Immunologie, Medizinische Universitätsklinik Freiburg, Freiburg, Germany</affiliation></author><author xml:id="author-29"><persName><forename type="first">M.</forename><surname>Schattenkirchner</surname></persName><affiliation>Rheumaeinheit, Medizinische Poliklinik der Universität München, Munchen, Germany</affiliation></author><author xml:id="author-30"><persName><forename type="first">K.</forename><surname>Krüger</surname></persName><affiliation>Rheumaeinheit, Medizinische Poliklinik der Universität München, Munchen, Germany</affiliation></author><author xml:id="author-31"><persName><forename type="first">R.</forename><surname>Sprekeler</surname></persName><affiliation>Diakoniekrankenhaus Rotenburg/Wümme, Rotenburg/Wümme, Germany</affiliation></author><author xml:id="author-32"><persName><forename type="first">H.</forename><surname>Waller</surname></persName><affiliation>Abteilung Innere Medizin II, Medizinische Klinik Tübingen, Tubingen, Germany</affiliation></author><author xml:id="author-33"><persName><forename type="first">J.</forename><surname>Saal</surname></persName><affiliation>Abteilung Innere Medizin II, Medizinische Klinik Tübingen, Tubingen, Germany</affiliation></author><author xml:id="author-34"><persName><forename type="first">H.</forename><surname>Warnatz</surname></persName><affiliation>Katholisches Krankenhaus Essen-Werden, Essen, Germany</affiliation></author><author xml:id="author-35"><persName><forename type="first">G.</forename><surname>Lemm</surname></persName><affiliation>Katholisches Krankenhaus Essen-Werden, Essen, Germany</affiliation></author><author xml:id="author-36"><persName><forename type="first">K.</forename><surname>Wilms</surname></persName><affiliation>Medizinische Poliklinik der Universität Würzburg, Wurzburg, Germany</affiliation></author><author xml:id="author-37"><persName><forename type="first">T.</forename><surname>Stolzenburg</surname></persName><affiliation>Medizinische Poliklinik der Universität Würzburg, Wurzburg, Germany</affiliation></author></analytic><monogr><title level="j">Rheumatology International</title><title level="j" type="sub">Clinical and Experimental Investigations</title><title level="j" type="abbrev">Rheumatol Int</title><idno type="journal-ID">296</idno><idno type="pISSN">0172-8172</idno><idno type="eISSN">1437-160X</idno><idno type="issue-article-count">9</idno><idno type="volume-issue-count">6</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="1992-11-01"></date><biblScope unit="volume">12</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="175">175</biblScope><biblScope unit="page" to="185">185</biblScope></imprint></monogr><idno type="istex">9D6BE8ED959279DE45398098C485ED3D9FAE729C</idno><idno type="DOI">10.1007/BF00302149</idno><idno type="ArticleID">BF00302149</idno><idno type="ArticleID">Art3</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1992-07-01</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Summary: The controlled clinical trial reported here is part of a multicenter clinical and basic research project, sponsored by the German Federal Minister of Science and Technology, directed by a standing commission of the president of the Max-Planck-Gesellschaft, and coordinated by the Max-Planck-Institut für Biochemie, München. Overall, 249 patients with rheumatoid arthritis (RA) were enrolled by 16 participating hospitals. In addition to NSAID treatment, patients were randomly given either interferon gamma (IFN-γ) or placebo. In the IFN-γ group, 107 patients were evaluated and in the control group, 116 patients were evaluated. The response rate after 3 months of treatment, according to joint pain indexes, was significantly higher in the IFN-γ group with an error probability of 1%. IFN-γ was able to reduce the quantity of corticosteroids administered. Compared with the control group, the IFN-γ group benefited considering all parameters measured. Most important side effects were transient fever and transient influenza-like symptoms; all other adverse events were comparable in both groups.</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>Medicine & Public Health</head><item><term>Rheumatology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1992-07-01">Created</change><change when="1992-11-01">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-11-22">References added</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2017-01-20">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/9D6BE8ED959279DE45398098C485ED3D9FAE729C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Springer, Publisher found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer-Verlag</PublisherName><PublisherLocation>Berlin/Heidelberg</PublisherLocation></PublisherInfo><Journal><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>296</JournalID><JournalPrintISSN>0172-8172</JournalPrintISSN><JournalElectronicISSN>1437-160X</JournalElectronicISSN><JournalTitle>Rheumatology International</JournalTitle><JournalSubTitle>Clinical and Experimental Investigations</JournalSubTitle><JournalAbbreviatedTitle>Rheumatol Int</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Medicine & Public Health</JournalSubject><JournalSubject Type="Secondary">Rheumatology</JournalSubject></JournalSubjectGroup></JournalInfo><Volume><VolumeInfo VolumeType="Regular" TocLevels="0"><VolumeIDStart>12</VolumeIDStart><VolumeIDEnd>12</VolumeIDEnd><VolumeIssueCount>6</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular"><IssueInfo TocLevels="0"><IssueIDStart>5</IssueIDStart><IssueIDEnd>5</IssueIDEnd><IssueArticleCount>9</IssueArticleCount><IssueHistory><CoverDate><Year>1992</Year><Month>11</Month></CoverDate></IssueHistory><IssueCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>1992</CopyrightYear></IssueCopyright></IssueInfo><Article ID="Art3"><ArticleInfo Language="En" ArticleType="OriginalPaper" NumberingStyle="Unnumbered" TocLevels="0" ContainsESM="No"><ArticleID>BF00302149</ArticleID><ArticleDOI>10.1007/BF00302149</ArticleDOI><ArticleSequenceNumber>3</ArticleSequenceNumber><ArticleTitle Language="En">Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis</ArticleTitle><ArticleCategory>Originals</ArticleCategory><ArticleFirstPage>175</ArticleFirstPage><ArticleLastPage>185</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2004</Year><Month>8</Month><Day>21</Day></RegistrationDate><Received><Year>1992</Year><Month>7</Month><Day>1</Day></Received><Accepted><Year>1992</Year><Month>7</Month><Day>2</Day></Accepted></ArticleHistory><ArticleCopyright><CopyrightHolderName>Springer-Verlag</CopyrightHolderName><CopyrightYear>1992</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants><ArticleContext><JournalID>296</JournalID><VolumeIDStart>12</VolumeIDStart><VolumeIDEnd>12</VolumeIDEnd><IssueIDStart>5</IssueIDStart><IssueIDEnd>5</IssueIDEnd></ArticleContext></ArticleInfo><ArticleHeader><AuthorGroup><InstitutionalAuthor><InstitutionalAuthorName>German Lymphokine Study Group</InstitutionalAuthorName></InstitutionalAuthor><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>P.</GivenName><GivenName>H.</GivenName><FamilyName>Hofschneider</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>U.</GivenName><FamilyName>Winter</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2" CorrespondingAffiliationID="Aff3"><AuthorName DisplayOrder="Western"><GivenName>E.</GivenName><GivenName>-M.</GivenName><FamilyName>Lemmel</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>B.</GivenName><FamilyName>Brölz</FamilyName></AuthorName><Role>main investigator</Role></Author><Author AffiliationIDS="Aff4"><AuthorName DisplayOrder="Western"><GivenName>W.</GivenName><FamilyName>Gaus</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff4"><AuthorName DisplayOrder="Western"><GivenName>S.</GivenName><FamilyName>Schmid</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff5"><AuthorName DisplayOrder="Western"><GivenName>H.</GivenName><GivenName>-J.</GivenName><FamilyName>Obert</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff5"><AuthorName DisplayOrder="Western"><GivenName>C.</GivenName><FamilyName>Stetter</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff6"><AuthorName DisplayOrder="Western"><GivenName>I.</GivenName><GivenName>O.</GivenName><FamilyName>Auer</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff6"><AuthorName DisplayOrder="Western"><GivenName>C.</GivenName><FamilyName>Papst</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff7"><AuthorName DisplayOrder="Western"><GivenName>W.</GivenName><GivenName>H.</GivenName><FamilyName>Boesken</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff7"><AuthorName DisplayOrder="Western"><GivenName>H.</GivenName><GivenName>E.</GivenName><FamilyName>Stierle</FamilyName><Suffix>II</Suffix></AuthorName></Author><Author AffiliationIDS="Aff8"><AuthorName DisplayOrder="Western"><GivenName>U.</GivenName><FamilyName>Botzenhardt</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff8"><AuthorName DisplayOrder="Western"><GivenName>W.</GivenName><FamilyName>Reemtsen</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff9"><AuthorName DisplayOrder="Western"><GivenName>D.</GivenName><FamilyName>Brackertz</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff9"><AuthorName DisplayOrder="Western"><GivenName>D.</GivenName><FamilyName>Richter</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff10"><AuthorName DisplayOrder="Western"><GivenName>V.</GivenName><FamilyName>Diehl</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff10"><AuthorName DisplayOrder="Western"><GivenName>A.</GivenName><GivenName>K.</GivenName><Particle>von</Particle><FamilyName>Kalle</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff11"><AuthorName DisplayOrder="Western"><GivenName>C.</GivenName><FamilyName>Gärtner</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff11"><AuthorName DisplayOrder="Western"><GivenName>S.</GivenName><FamilyName>Herzig</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff12"><AuthorName DisplayOrder="Western"><GivenName>J.</GivenName><FamilyName>Goronzy</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff12"><AuthorName DisplayOrder="Western"><GivenName>C.</GivenName><FamilyName>Weyand</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff13"><AuthorName DisplayOrder="Western"><GivenName>J.</GivenName><GivenName>R.</GivenName><FamilyName>Kalden</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff13"><AuthorName DisplayOrder="Western"><GivenName>F.</GivenName><FamilyName>Strobel</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff15"><AuthorName DisplayOrder="Western"><GivenName>K.</GivenName><FamilyName>Machalke</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff16"><AuthorName DisplayOrder="Western"><GivenName>H.</GivenName><GivenName>H.</GivenName><FamilyName>Peter</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff16"><AuthorName DisplayOrder="Western"><GivenName>S.</GivenName><FamilyName>Meske</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff17"><AuthorName DisplayOrder="Western"><GivenName>M.</GivenName><FamilyName>Schattenkirchner</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff17"><AuthorName DisplayOrder="Western"><GivenName>K.</GivenName><FamilyName>Krüger</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff18"><AuthorName DisplayOrder="Western"><GivenName>R.</GivenName><FamilyName>Sprekeler</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff19"><AuthorName DisplayOrder="Western"><GivenName>H.</GivenName><GivenName>D.</GivenName><FamilyName>Waller</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff19"><AuthorName DisplayOrder="Western"><GivenName>J.</GivenName><GivenName>G.</GivenName><FamilyName>Saal</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff20"><AuthorName DisplayOrder="Western"><GivenName>H.</GivenName><FamilyName>Warnatz</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff20"><AuthorName DisplayOrder="Western"><GivenName>G.</GivenName><FamilyName>Lemm</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff21"><AuthorName DisplayOrder="Western"><GivenName>K.</GivenName><FamilyName>Wilms</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff21"><AuthorName DisplayOrder="Western"><GivenName>T.</GivenName><FamilyName>Stolzenburg</FamilyName></AuthorName></Author><Affiliation ID="Aff1"><OrgName>Max-Planck-Institut für Biochemie</OrgName><OrgAddress><City>Martinsried</City></OrgAddress></Affiliation><Affiliation ID="Aff2"><OrgName>Staatliches Rheumakrankenhaus Baden-Baden</OrgName><OrgAddress><City>Baden Baden</City><Country>Germany</Country></OrgAddress></Affiliation><Affiliation ID="Aff4"><OrgName>Universität Ulm</OrgName><OrgAddress><City>Ulm</City><Country>Germany</Country></OrgAddress></Affiliation><Affiliation ID="Aff5"><OrgName>Bioferon biochemische Substanzen GmbH & Co.</OrgName><OrgAddress><City>Laupheim</City></OrgAddress></Affiliation><Affiliation ID="Aff6"><OrgName>Medizinische Universitätsklinik</OrgName><OrgAddress><Street>Luitpoldkrankenhaus</Street><City>Würzburg</City></OrgAddress></Affiliation><Affiliation ID="Aff7"><OrgDivision>Medizinische Abteilung</OrgDivision><OrgName>Krankenhaus der Barmherzigen Brüder Trier</OrgName><OrgAddress><City>Trier</City><Country>Germany</Country></OrgAddress></Affiliation><Affiliation ID="Aff8"><OrgName>Rheumatologische Abteilung, Rotes Kreuz-Krankenhaus Bremen</OrgName><OrgAddress><City>Bremen</City><Country>Germany</Country></OrgAddress></Affiliation><Affiliation ID="Aff9"><OrgName>St. Vincenz- und Elisabeth-Hospital Mainz</OrgName><OrgAddress><City>Mainz</City><Country>Germany</Country></OrgAddress></Affiliation><Affiliation ID="Aff10"><OrgName>Medizinische Universitätsklinik Köln</OrgName><OrgAddress><City>Koln</City><Country>Germany</Country></OrgAddress></Affiliation><Affiliation ID="Aff11"><OrgDivision>Krankenhaus Porz/Rhein</OrgDivision><OrgName>Abteilung Rheumatologie</OrgName><OrgAddress><City>Köln</City></OrgAddress></Affiliation><Affiliation ID="Aff12"><OrgName>Medizinische Poliklinik V Heidelberg</OrgName><OrgAddress><City>Heidelberg</City><Country>Germany</Country></OrgAddress></Affiliation><Affiliation ID="Aff13"><OrgName>Medizinische Klinik III und Institut für klinische Immunologie und Rheumatologie Erlangen</OrgName><OrgAddress><City>Erlangen</City><Country>Germany</Country></OrgAddress></Affiliation><Affiliation ID="Aff15"><OrgName>Klinik Lippe</OrgName><OrgAddress><City>Horn-Bad Meinberg</City></OrgAddress></Affiliation><Affiliation ID="Aff16"><OrgDivision>Abteilung Rheumatologie und klinische Immunologie</OrgDivision><OrgName>Medizinische Universitätsklinik Freiburg</OrgName><OrgAddress><City>Freiburg</City><Country>Germany</Country></OrgAddress></Affiliation><Affiliation ID="Aff17"><OrgDivision>Rheumaeinheit</OrgDivision><OrgName>Medizinische Poliklinik der Universität München</OrgName><OrgAddress><City>Munchen</City><Country>Germany</Country></OrgAddress></Affiliation><Affiliation ID="Aff18"><OrgName>Diakoniekrankenhaus Rotenburg/Wümme</OrgName><OrgAddress><City>Rotenburg/Wümme</City><Country>Germany</Country></OrgAddress></Affiliation><Affiliation ID="Aff19"><OrgDivision>Abteilung Innere Medizin II</OrgDivision><OrgName>Medizinische Klinik Tübingen</OrgName><OrgAddress><City>Tubingen</City><Country>Germany</Country></OrgAddress></Affiliation><Affiliation ID="Aff20"><OrgName>Katholisches Krankenhaus Essen-Werden</OrgName><OrgAddress><City>Essen</City><Country>Germany</Country></OrgAddress></Affiliation><Affiliation ID="Aff21"><OrgName>Medizinische Poliklinik der Universität Würzburg</OrgName><OrgAddress><City>Wurzburg</City><Country>Germany</Country></OrgAddress></Affiliation><Affiliation ID="Aff3"><OrgName>Staatliches Rheumakrankenhaus</OrgName><OrgAddress><Street>Rotenbachtalstrasse 5</Street><Postcode>W-7570</Postcode><City>Baden-Baden</City><Country>Germany</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En"><Heading>Summary</Heading><Para>The controlled clinical trial reported here is part of a multicenter clinical and basic research project, sponsored by the German Federal Minister of Science and Technology, directed by a standing commission of the president of the Max-Planck-Gesellschaft, and coordinated by the Max-Planck-Institut für Biochemie, München. Overall, 249 patients with rheumatoid arthritis (RA) were enrolled by 16 participating hospitals. In addition to NSAID treatment, patients were randomly given either interferon gamma (IFN-γ) or placebo. In the IFN-γ group, 107 patients were evaluated and in the control group, 116 patients were evaluated. The response rate after 3 months of treatment, according to joint pain indexes, was significantly higher in the IFN-γ group with an error probability of 1%. IFN-γ was able to reduce the quantity of corticosteroids administered. Compared with the control group, the IFN-γ group benefited considering all parameters measured. Most important side effects were transient fever and transient influenza-like symptoms; all other adverse events were comparable in both groups.</Para></Abstract><KeywordGroup Language="En"><Heading>Key words</Heading><Keyword>Interferon gamma</Keyword><Keyword>Rheumatoid arthritis</Keyword><Keyword>Controlled clinical trial</Keyword><Keyword>Multicenter</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis</title></titleInfo><name type="corporate"><namePart>German Lymphokine Study Group</namePart></name><name type="personal"><namePart type="given">P.</namePart><namePart type="given">H.</namePart><namePart type="family">Hofschneider</namePart><affiliation>Max-Planck-Institut für Biochemie, Martinsried</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">U.</namePart><namePart type="family">Winter</namePart><affiliation>Max-Planck-Institut für Biochemie, Martinsried</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal" displayLabel="corresp"><namePart type="given">E.</namePart><namePart type="given">-M.</namePart><namePart type="family">Lemmel</namePart><affiliation>Staatliches Rheumakrankenhaus Baden-Baden, Baden Baden, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Brölz</namePart><affiliation>Staatliches Rheumakrankenhaus Baden-Baden, Baden Baden, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role><description>main investigator</description></name><name type="personal"><namePart type="given">W.</namePart><namePart type="family">Gaus</namePart><affiliation>Universität Ulm, Ulm, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Schmid</namePart><affiliation>Universität Ulm, Ulm, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="given">-J.</namePart><namePart type="family">Obert</namePart><affiliation>Bioferon biochemische Substanzen GmbH & Co., Laupheim</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Stetter</namePart><affiliation>Bioferon biochemische Substanzen GmbH & Co., Laupheim</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I.</namePart><namePart type="given">O.</namePart><namePart type="family">Auer</namePart><affiliation>Medizinische Universitätsklinik, Luitpoldkrankenhaus, Würzburg</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Papst</namePart><affiliation>Medizinische Universitätsklinik, Luitpoldkrankenhaus, Würzburg</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W.</namePart><namePart type="given">H.</namePart><namePart type="family">Boesken</namePart><affiliation>Medizinische Abteilung, Krankenhaus der Barmherzigen Brüder Trier, Trier, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="given">E.</namePart><namePart type="family">Stierle II</namePart><affiliation>Medizinische Abteilung, Krankenhaus der Barmherzigen Brüder Trier, Trier, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">U.</namePart><namePart type="family">Botzenhardt</namePart><affiliation>Rheumatologische Abteilung, Rotes Kreuz-Krankenhaus Bremen, Bremen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W.</namePart><namePart type="family">Reemtsen</namePart><affiliation>Rheumatologische Abteilung, Rotes Kreuz-Krankenhaus Bremen, Bremen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Brackertz</namePart><affiliation>St. Vincenz- und Elisabeth-Hospital Mainz, Mainz, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Richter</namePart><affiliation>St. Vincenz- und Elisabeth-Hospital Mainz, Mainz, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V.</namePart><namePart type="family">Diehl</namePart><affiliation>Medizinische Universitätsklinik Köln, Koln, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="given">K.</namePart><namePart type="family">von Kalle</namePart><affiliation>Medizinische Universitätsklinik Köln, Koln, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Gärtner</namePart><affiliation>Krankenhaus Porz/Rhein, Abteilung Rheumatologie, Köln</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Herzig</namePart><affiliation>Krankenhaus Porz/Rhein, Abteilung Rheumatologie, Köln</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Goronzy</namePart><affiliation>Medizinische Poliklinik V Heidelberg, Heidelberg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Weyand</namePart><affiliation>Medizinische Poliklinik V Heidelberg, Heidelberg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="given">R.</namePart><namePart type="family">Kalden</namePart><affiliation>Medizinische Klinik III und Institut für klinische Immunologie und Rheumatologie Erlangen, Erlangen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Strobel</namePart><affiliation>Medizinische Klinik III und Institut für klinische Immunologie und Rheumatologie Erlangen, Erlangen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Machalke</namePart><affiliation>Klinik Lippe, Horn-Bad Meinberg</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="given">H.</namePart><namePart type="family">Peter</namePart><affiliation>Abteilung Rheumatologie und klinische Immunologie, Medizinische Universitätsklinik Freiburg, Freiburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Meske</namePart><affiliation>Abteilung Rheumatologie und klinische Immunologie, Medizinische Universitätsklinik Freiburg, Freiburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Schattenkirchner</namePart><affiliation>Rheumaeinheit, Medizinische Poliklinik der Universität München, Munchen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Krüger</namePart><affiliation>Rheumaeinheit, Medizinische Poliklinik der Universität München, Munchen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Sprekeler</namePart><affiliation>Diakoniekrankenhaus Rotenburg/Wümme, Rotenburg/Wümme, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="given">D.</namePart><namePart type="family">Waller</namePart><affiliation>Abteilung Innere Medizin II, Medizinische Klinik Tübingen, Tubingen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="given">G.</namePart><namePart type="family">Saal</namePart><affiliation>Abteilung Innere Medizin II, Medizinische Klinik Tübingen, Tubingen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Warnatz</namePart><affiliation>Katholisches Krankenhaus Essen-Werden, Essen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Lemm</namePart><affiliation>Katholisches Krankenhaus Essen-Werden, Essen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Wilms</namePart><affiliation>Medizinische Poliklinik der Universität Würzburg, Wurzburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Stolzenburg</namePart><affiliation>Medizinische Poliklinik der Universität Würzburg, Wurzburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper"></genre><originInfo><publisher>Springer-Verlag</publisher><place><placeTerm type="text">Berlin/Heidelberg</placeTerm></place><dateCreated encoding="w3cdtf">1992-07-01</dateCreated><dateIssued encoding="w3cdtf">1992-11-01</dateIssued><copyrightDate encoding="w3cdtf">1992</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Summary: The controlled clinical trial reported here is part of a multicenter clinical and basic research project, sponsored by the German Federal Minister of Science and Technology, directed by a standing commission of the president of the Max-Planck-Gesellschaft, and coordinated by the Max-Planck-Institut für Biochemie, München. Overall, 249 patients with rheumatoid arthritis (RA) were enrolled by 16 participating hospitals. In addition to NSAID treatment, patients were randomly given either interferon gamma (IFN-γ) or placebo. In the IFN-γ group, 107 patients were evaluated and in the control group, 116 patients were evaluated. The response rate after 3 months of treatment, according to joint pain indexes, was significantly higher in the IFN-γ group with an error probability of 1%. IFN-γ was able to reduce the quantity of corticosteroids administered. Compared with the control group, the IFN-γ group benefited considering all parameters measured. Most important side effects were transient fever and transient influenza-like symptoms; all other adverse events were comparable in both groups.</abstract><note>Originals</note><relatedItem type="host"><titleInfo><title>Rheumatology International</title><subTitle>Clinical and Experimental Investigations</subTitle></titleInfo><titleInfo type="abbreviated"><title>Rheumatol Int</title></titleInfo><genre type="journal" displayLabel="Archive Journal"></genre><originInfo><dateIssued encoding="w3cdtf">1992-11-01</dateIssued><copyrightDate encoding="w3cdtf">1992</copyrightDate></originInfo><subject><genre>Medicine & Public Health</genre><topic>Rheumatology</topic></subject><identifier type="ISSN">0172-8172</identifier><identifier type="eISSN">1437-160X</identifier><identifier type="JournalID">296</identifier><identifier type="IssueArticleCount">9</identifier><identifier type="VolumeIssueCount">6</identifier><part><date>1992</date><detail type="volume"><number>12</number><caption>vol.</caption></detail><detail type="issue"><number>5</number><caption>no.</caption></detail><extent unit="pages"><start>175</start><end>185</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1992</recordOrigin></recordInfo></relatedItem><identifier type="istex">9D6BE8ED959279DE45398098C485ED3D9FAE729C</identifier><identifier type="DOI">10.1007/BF00302149</identifier><identifier type="ArticleID">BF00302149</identifier><identifier type="ArticleID">Art3</identifier><accessCondition type="use and reproduction" contentType="copyright">Springer-Verlag, 1992</accessCondition><recordInfo><recordContentSource>SPRINGER</recordContentSource><recordOrigin>Springer-Verlag, 1992</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001548 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001548 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Rhénanie
|area= UnivTrevesV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:9D6BE8ED959279DE45398098C485ED3D9FAE729C
|texte= Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis
}}
| This area was generated with Dilib version V0.6.31. |  |